Objectives: Medical management based on palliative chemotherapy is currently the standard of care in malignant pleural mesothelioma (MPM). Median survival of 12–16 months has been reported with modern chemotherapy regimens with or without anti-angiogenic agents. Multimodality therapy incorporating … More
Main Navigation Menu
➤ Find Out Who Was Exposed to Asbestos and How
➤ North Carolina Asbestos Exposure Work / Job Sites
➤ Asbestos-Contaminated Talc Mesothelioma Lawsuits
➤ Mesothelioma / Lung Cancer / Asbestosis: Basic Facts
➤ How to Get Legal Compensation for Your Case
➤ Case Evaluation — Free. Confidential. No Obligation.
➤ Questions New Clients Have Asked Us (FAQs)
➤ Information About Our Law Firm
➤ Asbestos Attorney Tom Lamb
➤ Collection of News and Reports
You can use our Quick Contact Form to tell us about your case.
Recent News & Reports
Nivolumab prolongs PFS, OS in relapsed malignant mesothelioma
Nivolumab significantly prolonged PFS and OS compared with placebo for patients with [ relapsed mesothelioma ], according to findings presented at International Association for the Study of Lung Cancer World Conference on Lung Cancer. “Mesothelioma is predominately a disease that is not suitable … More
Alterations in BAP1 Are Associated with Cisplatin Resistance through Inhibition of Apoptosis in Malignant Pleural Mesothelioma
Purpose: The clinical standard treatment for patients with malignant pleural mesothelioma (MPM) includes a cisplatin-based chemotherapy, leading to reduction of tumor size in only a minority of patients. Predicting response to chemotherapy in patients with MPM by using a genetic marker would, … More
Incidence of mesothelioma and asbestosis by occupation in a diverse workforce
Objective: We sought to characterize detailed patterns of mesothelioma and asbestosis incidence in the workforce as part of an occupational disease surveillance program in Ontario, Canada. Methods: The Occupational Disease Surveillance System (ODSS) cohort was established using workers' … More
Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study
Background: Malignant pleural mesothelioma (MPM) has few treatment options. [ Keytruda (pembrolizumab) ] showed preliminary clinical benefit in programmed death ligand 1 (PD-L1)-positive MPM. We evaluated the efficacy and safety of [ Keytruda (pembrolizumab) ] monotherapy in patients with … More
Anti-Mesothelin CAR T cell therapy for malignant mesothelioma
Abstract Malignant mesothelioma (MM) is a treatment-resistant tumor originating in the mesothelial lining of the pleura or the abdominal cavity with very limited treatment options. More effective therapeutic approaches are urgently needed to improve the poor prognosis of MM patients. Chimeric … More